News

Antibody Discovery Strategic Business Report 2025 | Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030
Antibody discovery, crucial for developing targeted therapies in fields like oncology and autoimmune diseases, is evolving ...
Hosted on MSN1mon
Antibodies that recognize lipids: A new path for HIV vaccines and autoimmune disease treatments
Their work highlights antibody features that could help people design better vaccines for HIV and even autoimmune diseases. "This work gives us a clearer picture of how these antibodies interact ...
Labiotech.eu5d
Myasthenia gravis treatments: what’s on the horizon?
Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.
PipelineReview.com4h
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis
SEOUL, South Korea I June 02, 2025 I ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S.
Immunotherapy Drugs (Monoclonal Antibodies, Immunomodulators, Vaccine) Market Size, Share & Trends Analysis and Growth Forecasts, 2025-2030
The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...
PharmiWeb7d
Antibody Market to Grow from USD 266.83 Billion in 2024 to Over USD 581 Billion by 2034
The antibody market has become a cornerstone of modern biotechnology and pharmaceutical industries, underpinning a vast array of diagnostic and therapeutic applications. Antibodies, which are proteins ...